Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9721841 | 0.88 | SIGMAR1 (0.45) | SIGMAR1ADRA2AMEN1KMT2AACHE | |
| SCHEMBL14702320 | 0.84 | SIGMAR1 (0.48) | SIGMAR1ADRA2AMEN1KMT2AACHE | |
| SCHEMBL728785 | 0.83 | CYP2D6 (0.49) | SIGMAR1ADRA2AMEN1KMT2ACYP3A4 | |
| SCHEMBL9721549 | 0.81 | ACHE (0.41) | MEN1KMT2AACHEBCHEBACE1 | |
| SCHEMBL27657086 | 0.80 | CYP2D6 (0.43) | SIGMAR1ADRA2AMEN1KMT2AACHE | |
| SCHEMBL24097896 | 0.77 | CYP2D6 (0.46) | SIGMAR1ADRA2AMEN1KMT2AACHE | |
| SCHEMBL1731437 | 0.77 | MEN1 (0.46) | SIGMAR1ADRA2AMEN1KMT2AACHE | |
| SCHEMBL3271398 | 0.74 | LTA4H (0.60) | SIGMAR1MEN1KMT2AACHECYP3A4 | |
| SCHEMBL4512639 | 0.74 | LTA4H (0.60) | SIGMAR1MEN1KMT2AACHECYP3A4 | |
| SCHEMBL20571573 | 0.73 | CYP3A4 (0.59) | SIGMAR1ADRA2AMEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-7629466-B2 | Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-5674868-A | ADMINISTERING TO TREAT DISORDERS SUCH AS ANXIETY, PSYCHOSIS, DEPRESSION, SCHIZOPHRENIA, DURG ABUSE, MIGRAINE, EMESIS AND IRRITABLE BOWEL SYNDROME | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-07 | — | — | US | disclosed |
| EP-0669919-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012494-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-06-09 | — | — | WO | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5100903-A | Analgesics | ANAQUEST, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4994471-A | Analgesics, anesthetics | BOC, INC. (US) | 1991-02-19 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | CCKBR, GRPR, HRH2 | SIGMAR1 1311/4885ADRA2A 606/4885MEN1 783/4885 |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | SIGMAR1 924/4885ADRA2A 1143/4885MEN1 816/4885 |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | SIGMAR1 1935/4885ADRA2A 197/4885MEN1 3248/4885 |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | CCKBR, HRH2, GRPR | SIGMAR1 1300/4885ADRA2A 593/4885MEN1 1021/4885 |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | SIGMAR1 924/4885ADRA2A 1143/4885MEN1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.